Stocks
Arrowhead Pharmaceuticals Financial Statements (ARWR) |
||||||||||
| Arrowhead Pharmaceuticalssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 25.11.2019 | 23.11.2020 | 22.11.2021 | 28.11.2022 | 29.11.2023 | 08.08.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 168.8 | 88.0 | 138.3 | 243.2 | 240.7 | 19.6 | |||
| Operating Income, bln rub | 61.2 | -93.2 | -149.0 | -178.5 | -205.0 | -547.2 | ||||
| EBITDA, bln rub | ? | 65.6 | -87.2 | -132.6 | -162.3 | -175.7 | -508.3 | |||
| Net profit, bln rub | ? | 68.0 | -84.6 | -140.8 | -176.5 | -205.3 | -538.6 | |||
| OCF, bln rub | ? | 173.0 | -95.4 | 171.2 | -136.1 | -153.9 | -350.9 | |||
| CAPEX, bln rub | ? | 12.0 | 12.0 | 23.6 | 52.8 | 176.7 | 181.1 | |||
| FCF, bln rub | ? | 161.0 | -107.3 | 147.7 | -188.9 | -330.6 | -532.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 107.6 | 181.2 | 287.3 | 421.7 | 445.7 | 562.3 | ||||
| Cost of production, bln rub | 0.000 | 0.000 | 0.000 | 10.4 | 0.000 | 17.4 | ||||
| R&D, bln rub | 81.0 | 128.9 | 206.3 | 297.3 | 353.2 | 465.8 | ||||
| Interest expenses, bln rub | 6 958 | 9 191 | 6.12 | 5.03 | 18.3 | 23.0 | ||||
| Assets, bln rub | 349.8 | 522.5 | 710.1 | 691.9 | 765.6 | 883.8 | ||||
| Net Assets, bln rub | ? | 244.6 | 461.8 | 408.8 | 106.0 | 271.3 | 330.5 | |||
| Debt, bln rub | 0.000 | 21.1 | 25.5 | 81.6 | 115.2 | 454.1 | ||||
| Cash, bln rub | 258.7 | 315.5 | 367.8 | 376.4 | 403.6 | 436.7 | ||||
| Net debt, bln rub | -258.7 | -294.4 | -342.2 | -294.8 | -288.5 | 17.5 | ||||
| Ordinary share price, rub | 28.2 | 43.1 | 62.4 | 33.1 | 26.9 | 26.2 | ||||
| Number of ordinary shares, mln | 93.9 | 100.7 | 103.7 | 105.4 | 107.3 | 124.2 | ||||
| Market cap, bln rub | 2 645 | 4 337 | 6 477 | 3 484 | 2 883 | 3 249 | ||||
| EV, bln rub | ? | 2 386 | 4 043 | 6 135 | 3 190 | 2 595 | 3 266 | |||
| Book value, bln rub | 228 | 446 | 395 | 94 | 261 | 322 | ||||
| EPS, rub | ? | 0.72 | -0.84 | -1.36 | -1.67 | -1.91 | -4.34 | |||
| FCF/share, rub | 1.72 | -1.07 | 1.42 | -1.79 | -3.08 | -4.28 | ||||
| BV/share, rub | 2.42 | 4.43 | 3.81 | 0.89 | 2.43 | 2.59 | ||||
| EBITDA margin, % | ? | 38.9% | -99.1% | -95.9% | -66.7% | -73.0% | -2 587% | |||
| Net margin, % | ? | 40.3% | -96.1% | -101.9% | -72.6% | -85.3% | -2 741% | |||
| FCF yield, % | ? | 6.09% | -2.48% | 2.28% | -5.42% | -11.5% | -16.4% | |||
| ROE, % | ? | 27.8% | -18.3% | -34.5% | -166.6% | -75.7% | -163.0% | |||
| ROA, % | ? | 19.4% | -16.2% | -19.8% | -25.5% | -26.8% | -60.9% | |||
| P/E | ? | 38.9 | -51.3 | -46.0 | -19.7 | -14.0 | -6.03 | |||
| P/FCF | 16.4 | -40.4 | 43.9 | -18.4 | -8.72 | -6.11 | ||||
| P/S | ? | 15.7 | 49.3 | 46.8 | 14.3 | 12.0 | 165.4 | |||
| P/BV | ? | 11.6 | 9.72 | 16.4 | 37.1 | 11.0 | 10.1 | |||
| EV/EBITDA | ? | 36.4 | -46.4 | -46.3 | -19.7 | -14.8 | -6.43 | |||
| Debt/EBITDA | -3.94 | 3.37 | 2.58 | 1.82 | 1.64 | -0.03 | ||||
| R&D/CAPEX, % | 675.3% | 1 078% | 875.6% | 563.3% | 199.8% | 257.2% | ||||
| CAPEX/Revenue, % | 7.11% | 13.6% | 17.0% | 21.7% | 73.4% | 921.7% | ||||
| Arrowhead Pharmaceuticals shareholders | ||||||||||
